Skip to main content
Publications
Marsal JR, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights. Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Phiri K, Hallas J, Linder M, Margulia A, Suehs B, Arana A, Bahmanyar S, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Sahlertz Kristiansen N, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Poster presented at the American Urological Association 2020 Conference (Conference cancelled); May 2020. Washington, DC. [abstract] J Urol. 2020 Apr; 203(Supplement 4):e910-1. doi: 10.1097/JU.0000000000000931.010
Robertson G, Fleming A, Williams MC, Trucco E, Quinn N, Hogg RE, McKay GJ, Pellegrini E, Newby DE, van Beek EJ, Peto T, Dhillon B, van Hemert J, MacGillivray T. Screening for hypertension using retinal vascular calibre in ultra-widefield fundus imaging. Poster presented at the American Heart Association's Joint Hypertension 2018 Scientific Sessions; September 6, 2018. Chicago, IL. [abstract] Hypertension. 2018 Dec 6; 72:AP400. doi: 10.1161/hyp.72.suppl_1.P400